dolutegravir: Clinical Trials

47 trials of dolutegravir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

24 completed, 11 unknown, 4 recruiting, 3 withdrawn. 47 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 447Completed 24, Unknown 11, Recruiting 4, Withdrawn 3, Not yet recruiting 2, Active not recruiting 1, Enrolling by invitation 1, Terminated 1

Follow dolutegravir: new trials by email Literature Review of dolutegravir trials Research Report on dolutegravir

Trials (filtered) newest first · largest first

All 47 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Sleep Outcomes and Multidimensional Sleep Assessment - a Randomized Trial of Dolutegravir- vs Doravirine-based Antiretroviral Therapy in People Living With HIV
Tenofovir disoproxil fumarate 300mg / Lamivudine 300mg / Doravirine 100mg, Tenofovir disoproxil fumarate 300mg / Lamivudine 300mg / Dolutegravir 50mg - HIV (Human Immunodeficiency Virus), Sleep
Phase 4Not yet recruitingUniversity of Witwatersrand, South Africa402026-10-052026-10-06
Dolutegravir/Lamivudine in Treatment-Naïve Pregnant Women
Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO], TDF/XTC or TAF/FTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine) - HIV-1-infection
Phase 4RecruitingFundación Huésped2102026-09-102026-09-18
Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)
Dolutegravir 50 MG plus lamivudine 300 MG; Dolutegravir/lamivudine (50 MG/300 MG) - HIV, HIV-1
Phase 4RecruitingUBATEC502025-07-312025-09-12
Effect of Dolutegravir Compared With Darunavir/Cobicistat on the Severity of Neuropsychiatric Effects al 12 Weeks in Antirretroviral Treatment-Naive Adults.
Dolutegravir (DTG), Darunavir/Cobicistat (FDC) - HIV, Insomnia
Phase 4UnknownInstituto Mexicano del Seguro Social1402025-06-192025-06-26
Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)
DOVATO - HIV-1-infection, Opioid Use Disorder
Phase 4Not yet recruitingSaskatchewan Health Authority - Regina Area402024-09-302024-08-30
Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial
TLD - Tenofovir Disoproxil Fumarate / Lamivudine / Dolutegravir - HIV Prevention
Phase 4RecruitingUniversity of Witwatersrand, South Africa1002024-06-012026-06-09
B-free Multistage Trial
DOR/DTG/3TC - HIV, Drug Resistance
Phase 4Enrolling by invitationInsel Gruppe AG, University Hospital Bern2102023-11-132024-12-04
Doravirine Dose Optimisation in Pregnancy
Doravirine, Dolutegravir - HIV
Phase 4RecruitingUniversity of Liverpool762023-10-102026-02-19
Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day, Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day, Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine. - HIV Infections, Fatty Liver Disease
Phase 4CompletedFundacion SEIMC-GESIDA632023-05-262025-07-18
Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF Toxicity
Dolutegravir 50 MG plus lamivudine 300 MG; Dolutegravir/lamivudine (50 MG/300 MG) - Acquired Immunodeficiency Syndrome
Phase 4UnknownShanghai Public Health Clinical Center1002022-08-012022-08-09
Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin
Dolutegravir - Hiv, Tuberculosis
Phase 4CompletedHelen Reynolds362021-11-182024-08-13
Investigating the Interaction Between Two Long-acting Reversible Methods of Contraception and Dolutegravir, a Treatment for HIV
Dolutegravir, Levonorgestrel implant, Depo medroxyprogesterone acetate injection - Human Immunodeficiency Virus, Contraception
Phase 4UnknownBotswana Harvard AIDS Institute Partnership1402021-10-212023-07-27
Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)
Dolutegravir/Lamivudine - Human Immunodeficiency Virus
Phase 4UnknownSaint Michael's Medical Center402021-09-262023-10-11
Pharmacokinetics of Twice or Once Daily DTG (50mg) in Children With HIV and TB
Dolutegravir 50 MG, Dolutegravir 10 MG - Tuberculosis, Hiv
Phase 4UnknownUniversity of KwaZulu202021-08-192024-02-01
DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV:
Dolutegravir/Lamivudine as a single pill, Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill. - HIV-1-infection
Phase 4CompletedFundacion SEIMC-GESIDA5542021-07-142025-07-18
Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3
Intervention Arm: dolutegravir/lamivudine, Comparator ARM: TDF/XTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine) - HIV-1-infection
Phase 4CompletedFundación Huésped2652021-05-172025-07-30
Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil
Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO], Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO] - Hiv, HIV Infections
Phase 4UnknownThomas Benfield1262021-02-022021-05-27
Inflammation and Co-Infections in D²EFT
NRTIs, Darunavir, Ritonavir - HIV-infection/Aids, Human Herpesvirus 4 Infections
Phase 4WithdrawnKirby Institute2021-02-012020-11-10
Optimizing Malaria Treatment for HIV-Malaria Co-infected Individuals
Artemether-lumefantrine - HIV Coinfection, Malaria
Phase 4UnknownMakerere University8882021-01-182023-01-06
Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test
Lamivudine 300 MG, Emtricitabine / Tenofovir Disoproxil Pill - Hiv, HIV-1-infection
Phase 4CompletedFundacion IDEAA2442020-11-172024-02-21

Showing 20 of 47. Sign in to see all of them.

Conditions studied

Acquired Immunodeficiency Syndrome (16)  ·  HIV Infections (9)  ·  Body Weight Changes (2)  ·  Tuberculosis (2)  ·  Anxiety Disorders (1)  ·  Bone Diseases, Metabolic (1)  ·  Cardiovascular Abnormalities (1)  ·  Cardiovascular Diseases (1)  ·  Coinfection (1)  ·  Cytomegalovirus Infections (1)  ·  Depression (1)  ·  Epstein-Barr Virus Infections (1)  ·  HIV-Associated Lipodystrophy Syndrome (1)  ·  Infections (1)  ·  Inflammation (1)

Sponsors

Fundación Huésped (3)  ·  Kirby Institute (3)  ·  St Stephens Aids Trust (3)  ·  Fundacion SEIMC-GESIDA (2)  ·  Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (2)  ·  Thomas Benfield (2)  ·  University of Witwatersrand, South Africa (2)  ·  Andrew Carr (1)  ·  Augusta University (1)  ·  Botswana Harvard AIDS Institute Partnership (1)  ·  Charlotte-Paige Rolle, MD (1)  ·  Cristina Mussini (1)  ·  Emory University (1)  ·  Erasmus Medical Center (1)  ·  Fundacion Clinic per a la Recerca Biomédica (1)

Countries

Spain (8)  ·  Argentina (7)  ·  South Africa (7)  ·  United States (7)  ·  Brazil (4)  ·  Thailand (3)  ·  Uganda (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Denmark (2)  ·  India (2)  ·  Italy (2)  ·  Malaysia (2)  ·  Zimbabwe (2)  ·  Belgium (1)

Top investigators

Saye Khoo (2)  ·  Angela DM Kashuba, BScPhmPharmD (1)  ·  Bart Rijnders, MD, PhD (1)  ·  Cecile Lahiri, MD (1)  ·  Charlotte-Paige Rolle, MD (1)  ·  Chelsea Morroni, PhD MBChB (1)  ·  Esteban Martinez, MD (1)  ·  Ezequiel Cordova, MD (1)  ·  Flavia Kiweewa Matovu, MBChB, MSc (1)  ·  Francois WD Venter, PhD (1)  ·  Gail Matthews, MBBCh (1)  ·  Gail Matthews, MD (1)  ·  Gilles Wandeler, Prof (1)

Results publications

PMID 23824675, PMID 26856824, PMID 28537061, PMID 29107562, PMID 29617822, PMID 29643011, PMID 29912307, PMID 30005011, PMID 31033629, PMID 35411401, PMID 36259527, PMID 37207617, PMID 37342923, PMID 37604629, PMID 37908359, PMID 38023553, PMID 38652564, PMID 38721980, PMID 38788744, PMID 39578038, PMID 39826566, PMID 40023169, PMID 40354181, PMID 40489982, PMID 40874763, PMID 41083105, PMID 41779383, PMID 42162408

NIH funding

2017 (1), 2018 (1), K23AI124913 (1), R01AI122319 (1)